Evaluation of rotavirus vaccines in Asia--are there lessons to be learnt?
Rotavirus mortality is highest in the Asia-Pacific region and rotavirus vaccines could have enormous impact here. Yet, live-attenuated orally administered rotavirus vaccines have been evaluated in a small number of immunogenicity studies in some Asian countries, where the immune responses have been documented to be moderate in low-income countries with high diarrhoeal disease burden and mortality, and high in middle-/high-income countries with little reported rotavirus deaths. This review of these rotavirus clinical trials examines the results observed and attempts to draw lessons to inform decision-making, aid design of additional clinical trials and guide vaccine development by local manufacturers.
Mirzayeva
R
R
Program for Appropriate Technology in Health (PATH), Ferney-Voltaire, France.
Steele
A D
AD
Parashar
U D
UD
Zaman
K
K
Neuzil
K M
KM
Nelson
E A S
EA
D001208:Asia; D002986:Clinical Trials as Topic; D003967:Diarrhea / Q000517:prevention & control* / Q000821:virology; D006801:Humans; D007223:Infant; D012400:Rotavirus Infections / Q000517:prevention & control*; D022243:Rotavirus Vaccines / Q000008:administration & dosage / Q000276:immunology*; D014611:Vaccination
D022243:Rotavirus Vaccines